212 related articles for article (PubMed ID: 12612508)
21. Summaries for patients. Cost-effectiveness of screening and surveillance for Barrett esophagus.
Ann Intern Med; 2003 Feb; 138(3):I-41. PubMed ID: 12558382
[No Abstract] [Full Text] [Related]
22. Screening for Barrett's esophagus.
Spechler SJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S25-9. PubMed ID: 12478241
[TBL] [Abstract][Full Text] [Related]
23. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
24. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.
Omidvari AH; Hazelton WD; Lauren BN; Naber SK; Lee M; Ali A; Seguin C; Kong CY; Richmond E; Rubenstein JH; Luebeck GE; Inadomi JM; Hur C; Lansdorp-Vogelaar I
Gastroenterology; 2021 Aug; 161(2):487-494.e4. PubMed ID: 33974935
[TBL] [Abstract][Full Text] [Related]
25. Improving screening practices for Barrett's esophagus.
Shaheen NJ; Palmer LB
Surg Oncol Clin N Am; 2009 Jul; 18(3):423-37. PubMed ID: 19500734
[TBL] [Abstract][Full Text] [Related]
26. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations.
Hirst NG; Gordon LG; Whiteman DC; Watson DI; Barendregt JJ
J Gastroenterol Hepatol; 2011 Feb; 26(2):247-54. PubMed ID: 21261712
[TBL] [Abstract][Full Text] [Related]
27. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
28. Risk factors in the development of esophageal adenocarcinoma.
Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
[TBL] [Abstract][Full Text] [Related]
29. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?
Soni A; Sampliner RE; Sonnenberg A
Am J Gastroenterol; 2000 Aug; 95(8):2086-93. PubMed ID: 10950062
[TBL] [Abstract][Full Text] [Related]
30. Endoscopic surveillance of Barrett's esophagus: another viewpoint.
Richter JE
Am J Gastroenterol; 1993 May; 88(5):630-2. PubMed ID: 8480722
[No Abstract] [Full Text] [Related]
31. The wizards of odds: cost-effectiveness, Barrett's screening, and surveillance guidelines.
Perdue DG; Murray J; Wang KK
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):865-7. PubMed ID: 15476149
[No Abstract] [Full Text] [Related]
32. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: Is increased patient screening necessary?
Segel MC; Campbell WL; Medsger TA; Roumm AD
Gastroenterology; 1985 Sep; 89(3):485-8. PubMed ID: 3926590
[TBL] [Abstract][Full Text] [Related]
33. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival?
Dellon ES; Shaheen NJ
J Clin Oncol; 2005 Jul; 23(20):4478-82. PubMed ID: 16002837
[TBL] [Abstract][Full Text] [Related]
34. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study.
Lassen A; Hallas J; de Muckadell OB
Am J Gastroenterol; 2006 Jun; 101(6):1193-9. PubMed ID: 16771936
[TBL] [Abstract][Full Text] [Related]
35. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening.
Sami SS; Moriarty JP; Rosedahl JK; Borah BJ; Katzka DA; Wang KK; Kisiel JB; Ragunath K; Rubenstein JH; Iyer PG
Am J Gastroenterol; 2021 Aug; 116(8):1620-1631. PubMed ID: 34131096
[TBL] [Abstract][Full Text] [Related]
36. Screening and surveillance in Barrett's esophagus: a call to action.
Eisen GM; Lieberman D; Fennerty MB; Sonnenberg A
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):861-4. PubMed ID: 15476148
[No Abstract] [Full Text] [Related]
37. Gastroesophageal reflux and cancer.
Turcotte S; Duranceau A
Thorac Surg Clin; 2005 Aug; 15(3):341-52. PubMed ID: 16104125
[TBL] [Abstract][Full Text] [Related]
38. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux.
Lin OS; Schembre DB; Mergener K; Spaulding W; Lomah N; Ayub K; Brandabur JJ; Bredfeldt J; Drennan F; Gluck M; Jiranek GC; McCormick SE; Patterson D; Kozarek RA
Gastrointest Endosc; 2007 Apr; 65(4):577-83. PubMed ID: 17324414
[TBL] [Abstract][Full Text] [Related]
39. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus.
Rubenstein JH; Inadomi JM
J Clin Gastroenterol; 2006 Feb; 40(2):109-15. PubMed ID: 16394870
[TBL] [Abstract][Full Text] [Related]
40. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
